BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

BXPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

BXPHARMA 14-Sep-2021

(Cont. of BXPHARMA): Sanofi Bangladesh has over 800 employees and produces approximately 100 branded generic products, predominately for the local market. Sanofi Bangladesh has a strong presence in cardiology, diabetes, oncology, dermatology and CNS. Sanofi also supplies its global brands of vaccines, insulins and chemotherapy drugs to Bangladesh through direct imports, which the Group will continue to distribute following the completion of the Acquisition. (Cont. 4)

BXPHARMA 14-Sep-2021

(Cont. of BXPHARMA): Following a series of mergers, it became known as Sanofi-Aventis in 2004, before being renamed in 2013 as Sanofi Bangladesh Limited. Sanofi Bangladesh's state-of-the-art manufacturing facilities, including a PICIS certifiable manufacturing facility for the leading antibiotic, cephalosporin, are spread over c25 acres of land, located near Beximco Pharma's manufacturing facility in Tongi. (Cont. 3)

BXPHARMA 14-Sep-2021

(Cont. of BXPHARMA): while enabling the Company to consolidate its position as a leading pharmaceutical in Bangladesh by adding an established business with a reputation for high-quality products. Sanofi Bangladesh has been part Sanofi SA ("Sanofi"), a global biopharmaceutical company focused on human health. The operations in Bangladesh were established in 1958 as part of the British chemical company, May & Baker. (Cont. 2)

BXPHARMA 14-Sep-2021

Refer to the earlier news disseminated by DSE on 24 January 2021 and 05 September 2021, the Company has further informed that the company has now entered into the share purchase agreement to acquire the majority stake in Sanofi Bangladesh Limited ("Sanofi Bangladesh") (the "Acquisition"). The proposed earnings accretive Acquisition is in line with Beximco Pharma's strategy to expand its capabilities and product offering into new specialty therapy areas (Cont. 1)

BXPHARMA 05-Sep-2021

(Continuation news of BXPHARMA): As anticipated, the Company and the Vendor will now seek to execute the Share Purchase Agreement. Further announcements will be made in due course. (end)

BXPHARMA 05-Sep-2021

Refer to their earlier news disseminated by DSE on 24.01.2021 regarding proposed acquisition of a majority stake in Sanofi Bangladesh Limited, the Company has further informed that the Company's proposed acquisition of a majority stake in Sanofi Bangladesh Limited ("Sanofi Bangladesh") has been approved by the Foreign Exchange Investment Department of Bangladesh Bank. (cont.)

BXPHARMA 02-May-2021

(Continuation news of BXPHARMA) as Income from Vaccine Distribution: under the head Other Income. This is non-incurring one off contract and any future earning from this source is dependent on the delivery of the committed quantity of vaccine under the agreement (end)

BXPHARMA 02-May-2021

(Continuation news of BXPHARMA) delivered 5 million vaccines during the reported quarter. As per agreement, the Company is to receive fees for import, storage and delivery of the vaccine to the GOB warehouses across the country. A net amount of BDT. 383.70 million after deduction of related expenses from fees, has been reported (Cont-3)

BXPHARMA 02-May-2021

(Continuation news of BXPHARMA) the organic growth of business and hence the profit, part of this attributable to the income from Vaccine distribution and increased cash incentive from export. They also informed that they have entered into a tripartite agreement with the Government of Bangladesh (GOB) and the Serum Institute of India Pvt. Ltd. (SII), for the supply of 30 million doses of Oxford University-AstraZenca SARS-CoV-2 vaccine, AZD1222, in Bangladesh. The Company (Cont-2)

BXPHARMA 02-May-2021

(Q3 Un-audited): Consolidated EPS was Tk. 3.28 for January-March 2021 as against Tk. 2.02 for January-March 2020; Consolidated EPS was Tk. 8.23 for July 2020-March 2021 as against Tk. 5.84 for July 2019-March 2020. Consolidated NOCFPS was Tk. 9.05 for July 2020-March 2021 as against Tk. 9.83 for July 2019-March 2020. Consolidated NAV per share was Tk. 79.73 as on March 31, 2021 and Tk. 77.88 as on March 31, 2020. The company has informed that increased in EPS predominantly from (Cont-1)

Previous Next page